SHE2 Antibody

What is SHE protein and what cellular functions does it perform?

SHE (SH2 domain-containing adapter protein E) functions as an adapter protein containing an SH2 domain. This protein belongs to a family of signaling molecules that typically mediate protein-protein interactions in various signaling pathways. The SH2 domain specifically recognizes and binds to phosphorylated tyrosine residues, allowing SHE to participate in signal transduction mechanisms. In experimental settings, SHE protein has been detected in various tissues including pancreas and heart, suggesting its potential functional significance across multiple organ systems .

What applications is the SHE antibody validated for in research settings?

The SHE antibody (such as ab236588) has been experimentally validated for multiple research applications including Western Blot (WB) and Immunohistochemistry on paraffin-embedded sections (IHC-P). These validations encompass cross-species reactivity with human, mouse, and rat samples, making it versatile for comparative studies across these mammalian models. The antibody has demonstrated specific staining in human pancreatic tissue sections when used at a 1/100 dilution in IHC-P applications and produces successful results in Western blot analysis of rat and mouse heart lysates at a 1/500 dilution .

What is the molecular basis for SHE antibody specificity?

The specificity of the SHE polyclonal antibody derives from its immunogen design, which corresponds to a recombinant fragment protein within the human SHE amino acid sequence 1-200. This region contains epitopes that are sufficiently unique to generate antibodies that specifically recognize SHE protein. The polyclonal nature of the antibody means it recognizes multiple epitopes within this fragment, providing robust detection capability while maintaining specificity. This multi-epitope recognition contributes to the antibody's ability to detect SHE protein across species boundaries due to conserved amino acid sequences between human, mouse, and rat SHE proteins .

How can researchers optimize Western blot protocols specifically for SHE antibody detection?

Optimization of Western blot protocols for SHE antibody requires careful consideration of several parameters based on empirical data:

• Sample preparation: For heart tissue samples, standard RIPA buffer extraction has proven effective, with protein quantification ensuring equal loading (20-30 μg per lane recommended).

• Gel selection: Given the predicted band size of 54 kDa for SHE protein, a 10% SDS-PAGE gel provides optimal resolution.

• Transfer conditions: Semi-dry transfer at 15V for 60 minutes using PVDF membranes produces consistent results.

• Blocking conditions: 5% non-fat milk in TBST for 1 hour at room temperature minimizes background.

• Antibody dilution: The optimal dilution for SHE antibody is 1/500 in 2.5% BSA/TBST, incubated overnight at 4°C.

• Secondary antibody: Goat polyclonal to rabbit IgG at 1/50000 dilution provides excellent signal-to-noise ratio.

• Visualization: Both chemiluminescence and fluorescence detection systems are compatible, with exposure times adjusted based on expression levels .

What are the critical considerations when using the SHE antibody for immunohistochemistry on clinical specimens?

When utilizing SHE antibody for immunohistochemical analysis of clinical specimens, researchers should implement the following evidence-based parameters:

• Fixation protocol: Neutral-buffered formalin (10%) fixation for 24 hours followed by paraffin embedding preserves both antigenicity and tissue architecture.

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes has proven most effective for exposing SHE epitopes in formalin-fixed tissues.

• Blocking parameters: Endogenous peroxidase blocking (3% H₂O₂ for 10 minutes) followed by protein blocking (5% normal goat serum for 1 hour) minimizes non-specific staining.

• Antibody concentration: A 1/100 dilution in antibody diluent has consistently produced optimal signal-to-noise ratio in human pancreatic tissue.

• Incubation conditions: Primary antibody incubation overnight at 4°C followed by secondary antibody incubation for 1 hour at room temperature.

• Controls: Integration of both positive (known SHE-expressing tissue) and negative controls (primary antibody omission) is essential for result validation .

What approaches can mitigate cross-reactivity concerns when working with SHE antibody in complex tissue samples?

Cross-reactivity management requires systematic methodological approaches:

• Pre-adsorption testing: Incubating the SHE antibody with excess recombinant SHE protein (particularly the immunogen fragment aa 1-200) before application can confirm specificity through signal elimination.

• Orthogonal validation: Confirming results using alternative detection methods (e.g., mass spectrometry identification of immunoprecipitated proteins) strengthens confidence in antibody specificity.

• Knockout/knockdown controls: Testing the antibody on samples where SHE expression has been genetically reduced or eliminated provides the gold standard for specificity validation.

• Titration optimization: Determining the minimum effective antibody concentration reduces off-target binding while maintaining specific signal detection.

• Buffer optimization: Addition of 0.1-0.3% Triton X-100 in blocking buffers can reduce hydrophobic non-specific interactions in difficult tissues .

How should researchers design experiments to validate SHE antibody performance in new cell lines or tissues?

A systematic validation approach should include:

This systematic workflow ensures comprehensive validation before proceeding to experimental applications in novel systems .

What methodological approaches best integrate SHE antibody detection with phosphoprotein analysis?

For effective integration of SHE antibody in phosphoprotein studies, researchers should consider:

• Phosphatase inhibition: Sample preparation must include comprehensive phosphatase inhibitor cocktails (containing sodium orthovanadate, sodium fluoride, and β-glycerophosphate) to preserve phosphorylation states.

• Sequential immunoprecipitation: For interaction studies, performing immunoprecipitation with anti-phosphotyrosine antibodies followed by SHE antibody detection can reveal phosphorylation-dependent interactions.

• Parallel phospho-specific staining: Similar to phosphohistidine detection methodologies, comparing adjacent tissue sections stained with total SHE antibody versus phospho-specific antibodies can reveal activation patterns.

• Denaturing conditions: Careful optimization of SDS concentration in buffers is necessary to maintain phosphoepitope integrity while allowing SHE antibody access to its epitope.

• Signal amplification: For low-abundance phosphorylated forms, tyramide signal amplification can enhance detection sensitivity without compromising specificity .

How should researchers address discrepancies between SHE antibody results and genomic/transcriptomic data?

When faced with discordant results between protein detection and genomic/transcriptomic data:

• Post-transcriptional regulation assessment: Analyze miRNA databases for potential SHE-targeting regulatory elements that might explain protein-mRNA discrepancies.

• Protein stability analysis: Implement cycloheximide chase experiments to determine if SHE protein has unexpectedly long/short half-life explaining abundance differences.

• Epitope accessibility evaluation: Consider alternative sample preparation methods that might expose masked epitopes, particularly in highly structured or membrane-associated regions.

• Splice variant consideration: Review RNA-seq data for alternative splicing events that might generate protein isoforms lacking the antibody epitope region.

• Quantification method standardization: Ensure that protein quantification methods are accurately normalized to appropriate housekeeping controls that remain stable across experimental conditions.

• Technical versus biological replication: Distinguish between technical variation (same sample processed multiple times) and biological variation (different samples from same experimental group) when assessing result consistency .

What are the key considerations when applying SHE antibody in multiparametric imaging studies?

For multiparametric imaging applications featuring SHE antibody:

• Spectral overlap management: When combining fluorescent secondary antibodies, select fluorophores with minimal spectral overlap and implement appropriate compensation controls.

• Sequential staining protocols: For co-localization studies with potentially cross-reactive antibodies, sequential rather than simultaneous staining prevents epitope masking and cross-reactivity.

• Fixation compatibility: Different fixation protocols may preferentially preserve certain epitopes; comparative testing of paraformaldehyde versus methanol fixation can optimize multi-epitope detection.

• Antigen retrieval balancing: When multiple antibodies require different retrieval conditions, empirical testing of intermediate conditions is necessary to achieve acceptable detection of all targets.

• Three-dimensional reconstruction considerations: For tissue sections, z-stack acquisition with deconvolution enhances co-localization accuracy beyond single-plane imaging.

• Quantitative co-localization metrics: Implementation of Pearson's correlation coefficient or Manders' overlap coefficient provides objective measures of association beyond visual assessment .

What quality control measures confirm SHE antibody functionality before critical experiments?

Implementation of these quality control checkpoints ensures antibody reliability:

• Lot-to-lot validation: Each new antibody lot should be tested against a reference lot using identical samples and protocols to ensure consistent performance.

• Positive control inclusion: Regular testing with known SHE-expressing samples (e.g., heart tissue) confirms antibody functionality.

• Single-band verification: In Western blot applications, confirmation of a single band at the expected 54 kDa molecular weight indicates specificity.

• Signal-to-noise ratio assessment: Quantitative comparison of specific signal versus background should exceed a 5:1 ratio for optimal results.

• Cross-platform confirmation: Verification of consistent results across multiple detection platforms (e.g., immunohistochemistry and immunofluorescence) strengthens confidence in antibody reliability.

• Temperature stability monitoring: Antibody aliquots subjected to multiple freeze-thaw cycles should be periodically tested against fresh aliquots to detect potential degradation .

How can researchers differentiate between true SHE protein detection and common artifacts in immunostaining?

Distinguishing authentic SHE staining from artifacts requires systematic consideration of:

• Edge effects: True SHE staining should follow biologically relevant patterns, while artifactual staining often appears at tissue edges regardless of biological structures.

• Subcellular localization verification: SHE protein shows characteristic subcellular distribution patterns; deviation from expected localization suggests potential artifacts.

• Titration response: Authentic staining shows proportional intensity changes with antibody dilution, while artifacts often remain constant or show non-linear responses.

• Secondary-only controls: Parallel staining with secondary antibody alone identifies background contribution to the observed signal.

• Blocking peptide competition: Co-incubation of antibody with immunizing peptide should eliminate specific signal while leaving artifacts unchanged.

• Cross-validation with orthogonal methods: Confirmation of protein expression using alternative methods such as RNA-scope or mass spectrometry provides additional verification .

How might advances in antibody engineering improve next-generation SHE detection tools?

Emerging antibody technologies offer significant potential for enhanced SHE detection:

• Single-domain antibodies: Development of nanobodies (single-domain antibodies) against SHE would enable access to conformational epitopes with potentially higher specificity and tissue penetration.

• Site-specific conjugation: Advanced conjugation chemistries allow precise fluorophore attachment without compromising antigen-binding regions, enhancing signal consistency.

• Bispecific formats: Engineering bispecific antibodies targeting both SHE and its interaction partners would enable direct visualization of protein complexes in situ.

• Photoswitchable labels: Integration of photoswitchable fluorophores with SHE antibodies would enable super-resolution microscopy applications below the diffraction limit.

• Intracellular antibody fragments: Development of cell-permeable SHE antibody fragments could enable live-cell imaging of SHE dynamics without requiring genetic modification.

• Proximity labeling integration: Combining SHE antibodies with enzymes like APEX2 or TurboID would enable spatial proteomics to identify novel interaction partners in specific subcellular compartments .

What methodological approaches integrate SHE antibody detection with single-cell analysis technologies?

Integration strategies for single-cell applications include:

• Mass cytometry adaptation: Conjugation of SHE antibodies with rare earth metals enables integration into CyTOF panels for high-dimensional single-cell profiling.

• Oligonucleotide-tagged antibodies: Conversion of SHE antibodies to DNA-tagged versions enables compatibility with spatial transcriptomics and CITE-seq workflows.

• Microfluidic capture optimization: Buffer and fixation modifications for microfluidic-based single-cell protein detection require systematic optimization to maintain SHE epitope integrity.

• Image-based single-cell analysis: Integration of SHE immunofluorescence with cell segmentation algorithms enables correlation of protein expression with morphological features.

• In situ proximity ligation: Combining SHE antibody with antibodies against potential interaction partners in proximity ligation assays enables visualization of protein-protein interactions at the single-cell level.

• Single-molecule detection strategies: Development of ultrasensitive detection methods such as those demonstrated for other antibodies would enable quantification of low-abundance SHE protein in individual cells .